Shares of Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) fell 9.5% during trading on Tuesday . The company traded as low as $1.50 and last traded at $1.53. 23,196 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 31,001 shares. The stock had previously closed at $1.69.
Humacyte Stock Up 12.8 %
The stock’s 50-day moving average price is $2.31 and its 200 day moving average price is $1.58.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- What is a Bond Market Holiday? How to Invest and Trade
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Using the MarketBeat Stock Split Calculator
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Upcoming IPO Stock Lockup Period, Explained
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
